Turna Ray

Senior Editor

Phone Number

+1-212-651-5626

Email

Turna Ray at Genomeweb / 360dx Turna Ray at Genomeweb / 360dx

Turna Ray has been covering the personalized medicine and molecular diagnostics industries for GenomeWeb since 2006. She closely tracks the evolving regulatory, reimbursement, and business environment for precision medicine products.

Articles Authored by Turna Ray

Jun 14, 2019

Kura Oncology Garners Promising Data for T-cell Lymphoma Drug in Biomarker-Defined Population

Premium

CEO Troy Wilson unveiled the first data on tipifarnib demonstrating that biomarkers in the CXCL12 pathway identify which peripheral T-cell lymphoma patients respond best.

Jun 06, 2019

TAPUR Study Investigators Report First Positive Findings, Pursuing Tissue-Agnostic Cohorts

Premium

Keytruda and Ibrance demonstrate activity in molecularly defined populations, while a new cohort will explore Gilotrif in tumors with NRG1 fusions.

Jun 04, 2019

At ASCO, Real-World Data Shows Potential to Improve Precision Oncology

Premium

Researchers are collecting genomic and clinical data on cancer patients outside of clinical trials to understand tumor biology, treatment efficacy, and care gaps.

Jun 02, 2019

ASCO Studies Highlight Potential of Antibodies in Overcoming Anti-EGFR Rx Resistance in NSCLC

Premium

Instead of trying to tackle resistance by targeting rare mutations, researchers are looking to antibody based therapies that are more broadly active in lung cancer patients.

Jun 01, 2019

ASCO Studies Show Keytruda Increases Five Year Survival in NSCLC, Provides New Gastric Cancer Option

Premium

In the studies, the Merck immunotherapy extended survival for advanced lung cancer and stomach cancer patients with high PD-L1 expression.

May 30, 2019

Keytruda, Vitrakvi Approvals Spur Search for Other Targetable Biomarkers With Pan-Cancer Potential

Premium

The approval of two molecularly targeted, tissue-agnostic therapies, has shown researchers that there is a path forward for other pan-cancer markers.

May 29, 2019

Industry Interest in Pan-Cancer Indications Growing With FDA Support Despite Challenges

Premium

Tissue-agnostic drug development approaches have their own set of scientific and financial considerations, but some drugmakers are taking on those challenges.

May 16, 2019

Roche Drug Shows Benefit in Pediatric Patients With Rare, Molecularly Defined Tumors

Premium

In the Phase I/IB study, only patients with NTRK or ROS1 fusions, or an ALK fusion or mutation responded to entrectinib, while patients without these tumor markers didn’t respond.

Apr 22, 2019

WINTHER Trial Highlights Challenges, Potential of Transcriptomics for Precision Oncology

While the study didn't meet its primary endpoint, it showed the potential of transcriptomics to match cancer patients to beneficial treatments.

Apr 03, 2019

Project GENIE Used to Explore Impact of Rare Cancer Mutations on Treatment Response

Premium

Studies presented at the AACR meeting demonstrated how the registry can be used to evaluate how cancer patients with rare tumor markers respond to treatments.

Menu

Turna Ray

Kura Oncology Garners Promising Data for T-cell Lymphoma Drug in Biomarker-Defined Population

TAPUR Study Investigators Report First Positive Findings, Pursuing Tissue-Agnostic Cohorts

At ASCO, Real-World Data Shows Potential to Improve Precision Oncology

ASCO Studies Highlight Potential of Antibodies in Overcoming Anti-EGFR Rx Resistance in NSCLC

ASCO Studies Show Keytruda Increases Five Year Survival in NSCLC, Provides New Gastric Cancer Option

Keytruda, Vitrakvi Approvals Spur Search for Other Targetable Biomarkers With Pan-Cancer Potential

Industry Interest in Pan-Cancer Indications Growing With FDA Support Despite Challenges

Roche Drug Shows Benefit in Pediatric Patients With Rare, Molecularly Defined Tumors

WINTHER Trial Highlights Challenges, Potential of Transcriptomics for Precision Oncology

Project GENIE Used to Explore Impact of Rare Cancer Mutations on Treatment Response

Breaking News

Japan's National Cancer Center Adopts Qiagen Bioinformatics Platform for Precision Med Program

Roche's Rozlytrek Nets Japanese Approval in NTRK-Positive Pan Cancer Indication

European Commission Approves Lynparza for Advanced Ovarian Cancer With BRCA Mutations

FDA Approves Expanded Use of Agilent CDx for Keytruda in Head and Neck Cancer

Multi-Gene Panel Testing Finds Pathogenic Variant Carriers Missed Under Current Testing Guidelines

Saga Diagnostics Raises $4.2M

Sponsorships